Slide 1: BioSyent Inc. Q3/YTD 2025 Results
BioSyent BioSyentInc. Inc. Q4 / FY 2023 Q3/YTD 2025Results Results MARCH 13,20, 2024 NOVEMBER 2025 PRESENTED BY: RENÉ GOEHRUM PRESENTED BY: RENÉ GOEHRUM PRESIDENT AND CEO PRESIDENT AND CEO 1 | www.biosyent.com | TSXV: RX 1 | www.biosyent.com | TSXV: RX
Slide 2: Disclaimer
DISCLAIMER This presentation is for informational purposes only and should not be considered as an offer to buy or sell securities. No stock exchange has either approved or disapproved of the information that is contained in this presentation. This presentation may contain forward-looking statements
Slide 3: 3 | www.biosyent.com | TSXV: RX | www.biosyent.com | TSXV: RX
3 | www.biosyent.com | TSXV: RX 3 | www.biosyent.com | TSXV: RX
Slide 4: Sales, EBITDA and NIAT (Q3)
Sales, EBITDA and NIAT Quarter ended September 30th (Q3) 15,000 Highest ever quarterly sales +28% +35% 10,000 EBITDA(1) Margin: 30% to Sales CAD (000's) 5,000 +27% NIAT Margin: 22% to Sales +16% 12,222 8,871 2,900 2,351 9,556 2,850 2,308 3,632 2,682 0 Q3 2023 Q3 2024 Q3 2025 (1) Sales EBITDA NIAT 4
Slide 5: Sales, EBITDA and NIAT (YTD)
Sales, EBITDA and NIAT Nine months ended September 30th (YTD) 35,000 +27% Sales growth from Canadian Pharma, International Pharma and Legacy Businesses 30,000 +35% 25,000 20,000 EBITDA(1) Margin: 29% to Sales CAD (000's) 15,000 +35% NIAT Margin: 21% to Sales 10,000 +24% +66% 5,000 23,317 26,234 33,3
Slide 6: Q3/YTD 2025 Sales Summary ($)
Q3/YTD 2025 Sales Summary ($) Q3 ’25 Q3 ‘25 vs. YTD ’25 YTD ‘25 vs. Sales ($) Q3 ’24 (%) Sales ($) YTD ’24 (%) Canadian Pharma ($) $9,864k +19% $28,351k +16% Cathejell® -1% +5% Combogesic® -23% -25% FeraMAX® Pd +20% +16% Gelclair® -62% -49% Inofolic® +21% +63% RepaGyn® +2% -1% Tibella® (Canada) +32%
Slide 7: Fully Diluted Earnings per Share (TTM)
Fully Diluted Earnings per Share (TTM) TTM and Quarterly Fully Diluted EPS (CAD) 61 Consecutive 0.75 0.70 Profitable Quarters 0.60 0.60 to Q3 2025 0.50 0.42 0.40 0.30 0.20 0.23 0.20 0.20 0.20 0.18 0.14 0.15 0.13 0.12 0.12 0.10 0.10 0.00 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Slide 8: 2025 YTD Highlights
2025 YTD Highlights YTD 2025: First Tibelia® Global shipments made by BioSyent: ~$1.8 million in incremental revenue Further orders shipping Q4 2025 Mar/Jun/Sep 2025: Paid quarterly dividends of $0.05/share (+11% increase vs. 2024) Nov 2025: Q4 2025 Dividend of $0.05/share declared Apr 202
Slide 9: Most recommended iron supplement in Canada
Most recommended iron supplement in Canada - pharmacists and physicians - 10 consecutive years(1) Continued innovation and expansion of FeraMAX® product line for iron health (1) Based on Pharmacy Practice + Business, The Medical Post and Profession Santé 2025 Survey on OTC Counselling and Recomm
Slide 10: Innovations, Product Launches and Acquisitions
Innovations, Product Launches and Acquisitions Tibella® Jul 2020 FeraMAX® Pd Oct 2020 FeraMAX® Pd Therapeutic 150 Nov 2020 Combogesic® Dec 2020 FeraMAX® Pd Powder 15 Oct 2021 FeraMAX® Pd Maintenance 45 Mar 2023 Inofolic® Aug 2023 Gelclair® Nov 2023 Tibelia® Global Sep 2024 New endocrinology asset TB
Slide 11: 15 Years of Profitable Growth (and Counting!)
15 Years of Profitable Growth (and Counting!) 40,000 Tibelia Global Annual Revenue Annual NIAT 35,000 30,000 2010 – 2024 Growth: Revenue 21x 25,000 NIAT 140x CAD 000'S 20,000 15,000 10,000 5,000 0 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 *2025* f/d shares: 14,336,19
Slide 12: Cash Balance & Return on Equity (RoE)
Cash Balance & Return on Equity (“RoE”) Trailing Twelve Months ended September 30th 35,000 25% • Zero Debt 18% 22% 30,000 20% 20% • TTM Cash from Operations of 27,785 28,796 27,562 $8.1M 25,000 15% • TTM NCIB share buybacks: 20,000 $3.8M CAD (000's) RoE % 15,000 10% • TTM Dividends of $2.2M 10,000 5
Slide 13: Capital Allocation linked to Strategy
Capital Allocation linked to Strategy First use of capital is to generate revenue/profit growth & portfolio diversification. Capital Light, Cash-Generating Quarterly Dividends Business Model $6.7 M to Date Q4’22 – Q4’25 Share Buybacks $22.6 M to Date 3.1 million shares repurchased since 2018 •7 new
Slide 14: Stock Information
Stock Information As at November 18, 2025 Exchange & Trading Symbol 0% TSXV: RX Nov 18, 2025 Closing Stock Price (CAD) (TSXV): $10.76 52 Week Hi/Low (TSXV): $12.49 / $9.20 Issued Common Shares: 11,475,447 Treasury – RSU Shares in Trust (213,165) Outstanding Common Shares: 11,262,282 Options Outstand
Slide 15: Profitable. Well Capitalized. Growth Assets.
PROFITABLE. WELL CAPITALIZED. GROWTH ASSETS. FOCUSED ON LONG-TERM GROWTH AND TOTAL SHAREHOLDER RETURN. 15 www.biosyent.com | TSXV: RX
Slide 16: Reconciliation of EBITDA to NIAT
Reconciliation of EBITDA to NIAT 1.EBITDA is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA